

Table I-15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race and Sex

12 SEER Areas, 1999-2001

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females
All Sites	45.59	38.18	46.02	39.55	42.45	31.76
Invasive and In Situ	46.82	41.53	47.39	43.07	42.80	33.98
Oral cavity and Pharynx	1.37	0.67	1.38	0.68	1.32	0.50
Esophagus	0.77	0.26	0.79	0.25	0.76	0.36
Stomach	1.23	0.77	1.07	0.63	1.27	0.99
Colon and Rectum	5.90	5.54	5.95	5.52	4.92	5.39
Invasive and In Situ	6.23	5.79	6.26	5.76	5.25	5.68
Liver and Intrahepatic bile duct	0.88	0.42	0.72	0.35	0.91	0.36
Pancreas	1.24	1.23	1.25	1.20	1.25	1.35
Larynx	0.63	0.16	0.64	0.16	0.88	0.22
Invasive and In Situ	0.69	0.17	0.70	0.17	0.92	0.23
Lung and Bronchus	7.63	5.71	7.63	5.99	8.20	5.29
Melanoma of skin	1.89	1.28	2.27	1.55	0.10	0.06
Invasive and In Situ	3.02	2.06	3.59	2.48	0.12	0.10
Breast	0.12	13.39	0.12	14.21	0.16	9.99
Invasive and In Situ	0.13	15.96	0.14	16.88	0.18	12.02
Cervix uteri	-	0.77	-	0.74	-	0.95
Corpus and Uterus, NOS	-	2.62	-	2.82	-	1.74
Invasive and In Situ	-	2.66	-	2.87	-	1.76
Ovary	-	1.48	-	1.60	-	0.91
Prostate	17.81	-	17.58	-	20.58	-
Testis	0.35	-	0.42	-	0.10	-
Urinary bladder(Invasive and In Situ)	3.56	1.13	3.97	1.22	1.42	0.81
Kidney and Renal pelvis	1.49	0.90	1.57	0.93	1.35	0.92
Brain and Other nervous system	0.67	0.51	0.75	0.57	0.33	0.28
Thyroid	0.33	0.90	0.35	0.94	0.16	0.49
Hodgkin lymphoma	0.23	0.19	0.25	0.21	0.21	0.14
Non-Hodgkin lymphoma	2.18	1.80	2.31	1.91	1.21	1.04
Multiple myeloma	0.66	0.55	0.65	0.51	0.92	0.93
Leukemia	1.47	1.04	1.58	1.11	0.88	0.79
Acute Lymphocytic Leukemia	0.12	0.10	0.13	0.11	0.05	0.06
Chronic Lymphocytic Leukemia	0.50	0.31	0.55	0.34	0.28	0.20
Acute Myeloid Leukemia	0.45	0.35	0.47	0.36	0.30	0.29
Chronic Myeloid Leukemia	0.20	0.14	0.20	0.14	0.14	0.10

Devcan Version 5.2, April 2004, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Note: Invasive cancer only unless specified otherwise.